MDxHealth SA (NASDAQ:MDXH) Short Interest Update

MDxHealth SA (NASDAQ:MDXH) was the target of a large decline in short interest in the month of May. As of May 31st, there was short interest totalling 41,100 shares, a decline of 42.8% from the May 15th total of 71,900 shares. Based on an average daily volume of 67,700 shares, the short-interest ratio is currently 0.6 days. Currently, 0.1% of the shares of the company are short sold.

MDxHealth Stock Performance

Shares of MDXH traded down $0.01 on Monday, reaching $1.99. The company’s stock had a trading volume of 59,498 shares, compared to its average volume of 88,232. MDxHealth has a 12-month low of $1.35 and a 12-month high of $3.50. The stock has a market capitalization of $94.10 million, a P/E ratio of -1.31 and a beta of 1.30. The company has a debt-to-equity ratio of 3.14, a current ratio of 1.54 and a quick ratio of 1.45. The stock’s 50 day simple moving average is $1.85 and its two-hundred day simple moving average is $1.88.

MDxHealth (NASDAQ:MDXH) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). The business had revenue of $24.29 million for the quarter, compared to the consensus estimate of $22.62 million. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. Research analysts forecast that MDxHealth will post -1.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded MDxHealth to a “hold” rating in a research note on Saturday, May 24th.

Institutional Trading of MDxHealth

Hedge funds and other institutional investors have recently bought and sold shares of the stock. AWM Investment Company Inc. grew its stake in shares of MDxHealth by 10.6% during the 1st quarter. AWM Investment Company Inc. now owns 5,221,282 shares of the company’s stock valued at $7,414,000 after acquiring an additional 499,992 shares during the period. Delta Investment Management LLC boosted its position in shares of MDxHealth by 459.1% in the first quarter. Delta Investment Management LLC now owns 190,100 shares of the company’s stock worth $270,000 after purchasing an additional 156,100 shares during the period. Perkins Capital Management Inc. boosted its position in shares of MDxHealth by 20.1% in the first quarter. Perkins Capital Management Inc. now owns 1,181,475 shares of the company’s stock worth $1,678,000 after purchasing an additional 198,000 shares during the period. Castleview Partners LLC purchased a new stake in shares of MDxHealth in the first quarter worth $48,000. Finally, FAS Wealth Partners Inc. raised its position in shares of MDxHealth by 49.6% during the 4th quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company’s stock valued at $58,000 after purchasing an additional 8,100 shares during the period.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.